255 related articles for article (PubMed ID: 11016325)
1. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy.
Dyke CM; Bhatia D; Lorenz TJ; Marso SP; Tardiff BE; Hogeboom C; Harrington RA
Ann Thorac Surg; 2000 Sep; 70(3):866-71; discussion 871-2. PubMed ID: 11016325
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes.
Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators
N Engl J Med; 1998 Aug; 339(7):436-43. PubMed ID: 9705684
[TBL] [Abstract][Full Text] [Related]
3. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators.
Hasdai D; Holmes DR; Criger DA; Topol EJ; Califf RM; Wilcox RG; Paolasso E; Simoons M; Deckers J; Harrington RA
Am Heart J; 2000 Mar; 139(3):454-60. PubMed ID: 10689260
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Labinaz M; Kilaru R; Pieper K; Marso SP; Kitt MM; Simoons ML; Califf RM; Topol EJ; Armstrong PW; Harrington RA
Circulation; 2002 Jan; 105(3):322-7. PubMed ID: 11804987
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lauer MA; Houghtaling PL; Peterson JG; Granger CB; Bhatt DL; Sapp SK; Simoons ML; Harrington RA; Topol EJ; Lincoff AM;
Circulation; 2001 Dec; 104(23):2772-7. PubMed ID: 11733393
[TBL] [Abstract][Full Text] [Related]
6. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
Goa KL; Noble S
Drugs; 1999 Mar; 57(3):439-62. PubMed ID: 10193692
[TBL] [Abstract][Full Text] [Related]
7. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators.
Mahaffey KW; Harrington RA; Simoons ML; Granger CB; Graffagnino C; Alberts MJ; Laskowitz DT; Miller JM; Sloan MA; Berdan LG; MacAulay CM; Lincoff AM; Deckers J; Topol EJ; Califf RM
Circulation; 1999 May; 99(18):2371-7. PubMed ID: 10318656
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
Granada JF; Kleiman NS
Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
[TBL] [Abstract][Full Text] [Related]
9. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators.
Marso SP; Bhatt DL; Roe MT; Houghtaling PL; Labinaz M; Kleiman NS; Dyke C; Simmoons ML; Califf RM; Harrington RA; Topol EJ
Circulation; 2000 Dec; 102(24):2952-8. PubMed ID: 11113045
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience.
McClure MW; Berkowitz SD; Sparapani R; Tuttle R; Kleiman NS; Berdan LG; Lincoff AM; Deckers J; Diaz R; Karsch KR; Gretler D; Kitt M; Simoons M; Topol EJ; Califf RM; Harrington RA
Circulation; 1999 Jun; 99(22):2892-900. PubMed ID: 10359733
[TBL] [Abstract][Full Text] [Related]
12. Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Akkerhuis KM; Maas AC; Klootwijk PA; Krucoff MW; Meij S; Califf RM; Simoons ML
J Electrocardiol; 2000 Apr; 33(2):127-36. PubMed ID: 10819406
[TBL] [Abstract][Full Text] [Related]
13. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Schulman SP; Goldschmidt-Clermont PJ; Topol EJ; Califf RM; Navetta FI; Willerson JT; Chandra NC; Guerci AD; Ferguson JJ; Harrington RA; Lincoff AM; Yakubov SJ; Bray PF; Bahr RD; Wolfe CL; Yock PG; Anderson HV; Nygaard TW; Mason SJ; Effron MB; Fatterpacker A; Raskin S; Smith J; Brashears L; Gottdiener P; du Mee C; Kitt MM; Gerstenblith G
Circulation; 1996 Nov; 94(9):2083-9. PubMed ID: 8901655
[TBL] [Abstract][Full Text] [Related]
14. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
[TBL] [Abstract][Full Text] [Related]
15. Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass.
Dyke CM; Jennings LK; Maier G; Andreou C; Daly R; Tamberella MR
J Cardiovasc Pharmacol Ther; 2007 Mar; 12(1):54-60. PubMed ID: 17495258
[TBL] [Abstract][Full Text] [Related]
16. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Dyke CM
Am Heart J; 1999 Oct; 138(4 Pt 2):307-16. PubMed ID: 10502236
[TBL] [Abstract][Full Text] [Related]
17. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
Zeymer U
Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
[TBL] [Abstract][Full Text] [Related]
18. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
19. Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors.
Rasty S; Borzak S; Tisdale JE
J Clin Pharmacol; 2002 Dec; 42(12):1366-73. PubMed ID: 12463732
[TBL] [Abstract][Full Text] [Related]
20. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]